Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. OncoCyte's annualizedNet Income for the quarter that ended in Sep. 2022 was $-37.33 Mil. OncoCyte's average total tangible assets for the quarter that ended in Sep. 2022 was $56.66 Mil. Therefore, OncoCyte's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2022 was -65.89%.
The historical rank and industry rank for OncoCyte's Return-on-Tangible-Asset or its related term are showing as below:
OCX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -169 Med: -96.42 Max: -53.17
Current: -123.94
During the past 9 years, OncoCyte's highest Return-on-Tangible-Asset was -53.17%. The lowest was -169.00%. And the median was -96.42%.
OCX's Return-on-Tangible-Asset is ranked worse than 87.98% of 1581
companies
in the Biotechnology industry
Industry Median: -38.07
vs OCX: -123.94
OncoCyte Return-on-Tangible-Asset Historical Data
The historical data trend for OncoCyte's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
OncoCyte Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Return-on-Tangible-Asset
-169.00
-165.94
-90.84
-84.22
-158.54
OncoCyte Quarterly Data
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Return-on-Tangible-Asset
-94.67
-268.75
-94.73
-66.20
-65.89
Competitive Comparison
For the Biotechnology subindustry, OncoCyte's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoCyte Return-on-Tangible-Asset Distribution
For the Biotechnology industry and Healthcare sector, OncoCyte's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where OncoCyte's Return-on-Tangible-Asset falls in comparison to its industry or sector. The grey bar indicates the Return-on-Tangible-Asset's extreme value range as defined by GuruFocus.
OncoCyte Return-on-Tangible-Asset Calculation
OncoCyte's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Sep. 2022) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companyÂ’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companyÂ’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
OncoCyte Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of OncoCyte's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.02(3.41%) Volume: 412,414 3:59PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
OCX has been successfully added to your 
